September 20, 2017

New Haven drug developer Arvinas appoints CEO

Submitted photo
Submitted photo
John Houston

New Haven-based Arvinas LLC, a private biotechnology company creating a new class of drugs aimed at fighting cancer, has appointed John Houston as president and CEO.

Houston also will join the board of directors of Arvinas Holding Co. LLC, and its subsidiaries. He joined Arvinas in January as president of research and development and chief scientific officer, charged with leading discovery, translational and early clinical development research efforts.

Arvinas is developing new small molecules ‒ known as PROTACs (short for proteolysis targeting Ccimeras) ‒ aimed at attacking disease-causing cellular proteins. Based on research conducted at Yale University by Dr. Craig Crews, founder and chief scientific adviser, the company says it hopes its research translates into drugs that treat cancer and other diseases.

Houston has more than 28 years of experience in the pharmaceutical industry and spent the last 18 years at Bristol-Myers Squibb serving in multiple positions of increasing responsibility. Notably, he served on the executive team that drove decision-making on drugs such as daclatasvir (Daklinza), dapagliflozin (Farxiga), apixaban (Eliquis), ipilimumab (Yervoy) and nivolumab (Opdivo).

Free E-Newsletters

Sign up now for our daily and weekly
e-newsletters! Click Here

Today's Poll Is Connecticut a smart location for a second Amazon headquarters?<>
Most Popular on Facebook
Copyright 2017 New England Business Media